Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists may improve atrial fibrillation outcomes in diabetic patients.
A comprehensive, individualized approach incorporating novel antidiabetic therapies like SGLT2 inhibitors and GLP-1 receptor agonists may improve outcomes in patients with coexisting diabetes and atrial fibrillation.
Absolute Event Rate: 0% vs 0%
Diabetes mellitus and atrial fibrillation (AF) are two global epidemics that frequently coexist, with diabetes mellitus contributing to both an increased risk of new-onset AF and a worse prognosis. Pathophysiological mechanisms underlying this relationship include chronic inflammation, oxidative stress, atrial remodeling, autonomic dysfunction, advanced glycation end-products and epicardial adiposity. Management remains challenging; however, recent advances offer promise, including guideline-directed anticoagulation, tailored rate and rhythm control, and particularly, novel antidiabetic therapies, such as sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, may improve AF outcomes. A comprehensive, individualized approach is essential to mitigate morbidity and mortality in this high-risk population.
Karanikola et al. (Wed,) reported a other. Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists may improve atrial fibrillation outcomes in diabetic patients.